1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Sage Ready To Turn Over Cards On Bets Outside Of Depression

Five Clinical Trial Readouts Expected In 2024

 
• By Mandy Jackson

Sage has two postpartum depression drugs on the market, but will read out mid-stage trials this year for two candidates in Huntington’s, Parkinson’s and Alzheimer’s diseases and essential tremor.

Set of abstract dots and lines brain logotypes concept
Sage has multiple brain health program readouts in 2024 • Source: Shutterstock

The US Food and Drug Administration review last year regarding Sage Therapeutics, Inc./Biogen, Inc.’s Zurzuvae (zuranolone) was not a sure bet and resulted in a split decision – approval for postpartum depression (PPD), but not for major depressive disorder (MDD). This year, Sage is focused on Zurzuvae’s PPD launch, while also preparing to turn over the cards on two new bets, both outside of the depression market.

Key Takeaways

  • 2024 is a big one for Sage as it is the first full launch year for Zurzuvae (zuranolone) in postpartum depression, but the company is also expecting several data readouts from its R&D pipeline.

Zurzuvae, an oral positive allosteric modulator (PAM) of the GABA-A receptor, is Sage’s second drug for PPD after the approval...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 
• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

More from R&D

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Ireland’s Got Biopharma Talent To Keep Leading The Pack

 
• By Kevin Grogan

The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.